Juliana Peixoto

Dr. Juliana Peixoto


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Molecules
Verified
Journal Article
Open access
PDF file
JPJuliana Peixoto
Juliana Peixoto
Adriane OliveiraAdriane Oliveira
Adriane Oliveira
PMPatrícia Queiroz Monteiro
Patrícia Queiroz Monteiro
LGLuiz Filipe Gonçalves-Oliveira
Luiz Filipe Gonçalves-Oliveira
VAValter Viana Andrade-Neto
Valter Viana Andrade-Neto
Carlos Roberto AlvesCarlos Roberto Alves
Carlos Roberto Alves
Epoxy-α-lapachone (Lap) and Epoxymethyl-lawsone (Law) are oxiranes derived from Lapachol and have been shown to be promising drugs for Leishmaniases treatment. Although, it is known the action spectrum of both compounds affect the Leishmania spp. multiplication, there are gaps in the molecular binding details of target enzymes related to the parasite’s physiology. Molecular docking assays simulations were performed using DockThor server to predict the preferred orientation of both compounds to form stable complexes with key enzymes of metabolic pathway, electron transport chain, and lipids metabolism of Leishmania spp. This study showed the hit rates of both compounds interacting with lanosterol C-14 demethylase (−8.4 kcal/mol to −7.4 kcal/mol), cytochrome c (−10.2 kcal/mol to −8.8 kcal/mol), and glyceraldehyde-3-phosphate dehydrogenase (−8.5 kcal/mol to −7.5 kcal/mol) according to Leishmania spp. and assessed compounds. The set of molecular evidence reinforces the potential of both compounds as multi-target drugs for interrupt the network interactions between parasite enzymes, which can lead to a better efficacy of drugs for the treatment of leishmaniases.

6 January 2026 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
FAFrancisco Alexandrino-Junior
Francisco Alexandrino-Junior
GBGabriel Barcellos
Gabriel Barcellos
LGLuiz Filipe Gonçalves-Oliveira
Luiz Filipe Gonçalves-Oliveira
LCLuzia Cortes
Luzia Cortes
FSFranklin Souza Silva
Franklin Souza Silva
HRHelvécio Vinícius Antunes Rocha
Helvécio Vinícius Antunes Rocha
Background/Objectives: Cutaneous leishmaniasis (CL) remains a global health challenge, with treatment options often limited by drug resistance and systemic toxicity. Amphotericin B (AmB) represents a promising alternative. but intravenous administration causes severe systemic adverse effects. Despite growing interest in topical therapies, knowledge gaps remain regarding the comparative efficacy of delivery systems, including the influence of treatment timing and potential intrinsic effects. This study aimed to develop and characterize different topical AmB formulations (polymeric nanoparticles (PCL-AmB), a lipid-based (Oil_AmB) formulation, and a gel emulsion) to evaluate their in vivo efficacy against CL in a murine model, considering treatment initiation timing and potential intrinsic effects of the delivery systems. Methods: Formulations were prepared and characterized in terms of hydrodynamic size, polydispersity index, and AmB content. Antileishmanial activity was assessed in two independent in vivo experiments, with topical monotherapy administered five days per week for four weeks, starting either 10 or 30 days post-infection, representing early and established chronic stages of infection, respectively. Results: All formulations exhibited nanoscale dimensions and high homogeneity, with the lipid system demonstrating superior AmB solubilization. Both PCL-AmB and Oil_AmB reduced parasite load in the footpad, with Oil_AmB also reducing parasite load in draining lymph nodes. Conclusions: PCL-AmB and Oil_AmB reduced lesions and parasite burden in L. amazonensis-infected mice. Treatment timing was critical, with early Oil_AmB also reducing parasite loads in draining lymph nodes. These findings suggest that topical AmB formulations may provide a promising alternative for CL treatment, though further studies are required to optimize efficacy and administration schedules.

31 October 2025 in Experimental and Molecular Pathology
Verified
Journal Article
Open access
LGLuiz Filipe Gonçalves-Oliveira
Luiz Filipe Gonçalves-Oliveira
JPJuliana Peixoto
Juliana Peixoto
BPBernardo A. S. Pereira
Bernardo A. S. Pereira
Nathalia Silva Carlos OliveiraNathalia Silva Carlos Oliveira
Nathalia Silva Carlos Oliveira
FCFlávia de Oliveira Cardoso
Flávia de Oliveira Cardoso
Carlos Roberto AlvesCarlos Roberto Alves
Carlos Roberto Alves
The development of innovative treatments for American Cutaneous Leishmaniasis is crucial due to severe side effects of current treatment and the emergence of non-responder parasites. To address such a challenge the incorporation of epoxy-α-lapachone (ELAP) into a microemulsion (ME), named ELAP-ME, represents a promising therapeutic approach. In previous studies, ELAP-ME demonstrated efficacy in controlling infection in the BALB/c-Leishmania (Leishmania) amazonensis model, advancing in the technology readiness level with a drug prototype. To further validate its potential as a drug prototype, the histopathological effects of ELAP-ME were investigated in healthy BALB/c mice as a preclinical approach stage. Mice were administered with a fixed dose of ELAP-ME microemulsion (∼7 μg/kg) and evaluated at different short-term after administration (4, 12, and 24 h). Histopathological analysis of the liver, kidney, lung, heart, and brain revealed only mild alterations. These findings confirm the low toxicity profile of ELAP-ME, highlighting its safety and supporting its continued advancement as a pharmacological alternative for the treatment of leishmaniasis.